Can semaglutide really cut asthma attacks by 40%?
Yes, in a large UK real-world analysis presented at the 2026 European Respiratory Society Congress, adults on semaglutide had about 40% fewer asthma attacks and 20% fewer COPD flare-ups than adults on an older diabetes pill. Six years of similar cohort work points the same way. It isn't yet a lung treatment: no randomized trial has tested semaglutide with asthma or COPD as its main endpoint, and no respiratory guideline endorses it. But if you already qualify for semaglutide for weight or diabetes and you have asthma or COPD, that possible bonus is now worth raising with the doctor who manages your lungs.
The headline came out of Barcelona, from an electronic-health-records analysis by researchers at Imperial College London. The lead investigator, Chloe Bloom, put it plainly at the podium: encouraging, but not a reason to change any treatment yet. It's a conference abstract, not a peer-reviewed paper.
Not a one-off
What's made the study land harder than the usual conference abstract is that its numbers don't sit alone. Similar work has been pointing the same direction for six years, across different countries, different databases, and different comparator drugs.
| Study | Population | Comparator | What it found |
|---|---|---|---|
| ERS 2026 CPRD abstract (Bloom/Lee) | UK adults with type 2 diabetes plus asthma or COPD | Sulfonylurea | About 38% fewer asthma attacks; 21% fewer COPD flare-ups |
| Foer 2020 cohort | US adults with type 2 diabetes plus asthma | Sulfonylurea, DPP-4 inhibitor, insulin, SGLT-2 inhibitor | Fewer attacks against every comparator (about 45% to 66%) |
| Pradhan 2022 (BMJ) | UK adults with type 2 diabetes plus COPD | Sulfonylurea | 30% fewer severe flares; 37% fewer moderate flares |
| Huang 2026 target-trial emulation | Adults with obesity plus COPD | Other weight-loss drugs | 21% fewer COPD flares, 45% less respiratory failure, 57% lower all-cause death |
| Kaplan 2025 OPCRD cohort | Over 60,000 adults with obesity plus high-risk asthma | Non-users | Roughly double the odds of controlled asthma; no clear cut in exacerbation count |
| Hilberg 2022 RCT (liraglutide) | 40 adults with obesity plus COPD | Placebo | Better forced vital capacity and symptoms; no change in FEV1 |
The effect keeps landing somewhere in the 20% to 40% range for flares in people with airway disease who are also carrying diabetes or obesity. When independent datasets built with different comparators point the same way, residual confounding gets harder to blame.
Weight loss, and something else
The obvious question is whether this is just weight loss doing the work. Semaglutide drops around 15 kg on average in dedicated weight trials, and abdominal fat physically restricts breathing by pushing the diaphragm upward. Some of the benefit is almost certainly that. Probably not all of it. GLP-1 receptors sit on airway epithelium, smooth muscle, and eosinophils, and human tissue work shows the drug relaxes bronchi through the same cAMP pathway a rescue inhaler uses. In blood, it lowers IL-6, TNF-alpha, and periostin, all markers tied to airway inflammation. That biology helps explain why the effect survives adjustment for weight in some cohorts.
The one dedicated randomized trial here, 40 people on liraglutide (a related GLP-1 drug) for 40 weeks in obesity plus COPD, improved forced vital capacity and symptoms but didn't budge FEV1. The drug seems to change how these lungs work day-to-day without reversing the underlying airflow obstruction that defines COPD. That fits the cohorts: fewer exacerbations and better control, without much movement on spirometry.
What no guideline endorses yet
No respiratory guideline currently recommends semaglutide as a lung treatment. The 2026 GINA asthma strategy mentions GLP-1 drugs only as an emerging area in adults with obesity. The 2026 GOLD COPD report discusses them for obesity and sleep apnea as comorbidities, not as a COPD therapy. The FDA label covers type 2 diabetes, cardiovascular risk in diabetes, and chronic weight management, and nothing pulmonary; any respiratory use is off-label.
The label also warns that pulmonary aspiration has occurred in GLP-1 users going under general anesthesia or deep sedation, because the drug slows gastric emptying. If you take semaglutide and have a procedure scheduled, tell the anesthesiologist. And persistence matters: about half of routine users stop within a year, and any respiratory benefit only counts while you're actually on the drug.
What it changes for you
If you have obesity plus asthma or COPD and already qualify for semaglutide, whether for diabetes, cardiovascular risk, or weight, the possible respiratory bonus is worth raising with whoever manages your lungs. That's a defensible conversation now, and it wasn't six months ago. Keep your inhalers. Keep your biologic if you're on one. The trial that would let anything replace them hasn't been done. If you don't otherwise qualify, and your airway disease is well controlled at a healthy weight, the evidence isn't yet strong enough to start semaglutide for the lungs alone.
What would settle it
What would move this from an interesting side benefit to a lung treatment is straightforward: a randomized trial in adults with asthma or COPD that uses exacerbations as its pre-specified primary endpoint, with a mediation analysis separating weight loss from any direct airway effect, and peer-reviewed publication of the CPRD analysis with funding and industry-tie disclosures. Until then, Bloom's line from the podium is the right one. Strong enough to raise with your lung doctor. Not yet strong enough to prescribe on.